Long-Term Outcome of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy

Author:

Jensen Morten Kvistholm1,Almaas Vibeke Marie1,Jacobsson Linda1,Hansen Peter Riis1,Havndrup Ole1,Aakhus Svend1,Svane Bertil1,Hansen Thomas Fritz1,Køber Lars1,Endresen Knut1,Eriksson Maria J.1,Jørgensen Erik1,Amlie Jan Peder1,Gadler Fredrik1,Bundgaard Henning1

Affiliation:

1. From the Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (M.K.J., O.H., L.K., E.J., H.B.); Oslo University Hospital, Rikshospitalet, Oslo, Norway (V.M.A., S.A., K.E., J.P.A.); Karolinska University Hospital, Stockholm, Sweden (L.J., B.S., M.J.E., F.G.); and Copenhagen University Hospital, Gentofte Hospital, Gentofte, Denmark (P.R.H., T.F.H.).

Abstract

Background— Single-center reports on percutaneous transluminal septal myocardial ablation (PTSMA) in patients with hypertrophic obstructive cardiomyopathy have shown considerable differences in outcome. Methods and Results— We report the long-term outcome of 313 PTSMA procedures performed in 279 patients with hypertrophic obstructive cardiomyopathy aged 59±14 years from 1999 to 2010 in 4 Scandinavian centers. Sixty-nine percent of patients had ≥1 comorbidity at baseline. The median (interquartile range) of left ventricular outflow tract gradient at rest was reduced from 58 mm Hg (34 to 89 mm Hg) at baseline to 12 mm Hg (8 to 24 mm Hg) at 1-year ( P <0.001) and during Valsalva maneuver from 93 mm Hg (70 to 140 mm Hg) to 21 mm Hg (11 to 42 mm Hg) ( P <0.001). The proportion of patients with syncope was reduced from 18% to 2% ( P <0.001), and the proportion in New York Heart Association class III/IV was reduced from 94% to 21% ( P <0.001). All treatment effects remained stable during the follow-up. New York Heart Association class III/IV at the most recent follow-up (2.9±2.6 years) was associated with diabetes mellitus ( P =0.03), chronic obstructive pulmonary disease ( P =0.02), and valve disease unrelated to hypertrophic cardiomyopathy ( P <0.01). In-hospital mortality was 0.3%. The 1-, 5- and 10-year survival rates were 97%, 87%, and 67%, respectively ( P =0.06 versus an age- and sex-matched background population) in all patients and 99%, 94%, and 88%, respectively ( P =0.12) in patients aged <60 years (48±9 years, n=141). Age (hazard ratio, 1.07; 95% CI, 1.03 to 1.1) was the only predictor of survival. Conclusions— In this multicenter study, the in-hospital mortality after PTSMA was low despite considerable comorbidities. The hemodynamic and symptomatic effects were sustained long term. The long-term symptomatic outcome was associated with baseline comorbidities. The 10-year survival rate was comparable to that in an age- and sex-matched background population, and age was the only predictor of survival.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3